Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3401 Target Snapshot

Nuclear receptor subfamily 1 group I member 2 · SINGLE PROTEIN · Homo sapiens

3,575Compounds
678Assays
43Approved Drugs
1,921.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt O75469. Use UniProt O75469 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt O75469 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Nuclear receptor subfamily 1 group I member 2 as ChEMBL target CHEMBL3401, mapped to UniProt O75469. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Nuclear receptor subfamily 1 group I member 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL3401
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
O75469
Nuclear receptor subfamily 1 group I member 2
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Nuclear receptor subfamily 1 group I member 2 is the right protein anchor across sources, using UniProt O75469 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelNuclear receptor subfamily 1 group I member 2
UniProt AccessionO75469
Component TypeProtein
Sequence Length434 aa

Nuclear receptor subfamily 1 group I member 2

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Nuclear receptor subfamily 1 group I member 2, mapped to UniProt O75469. Sequence length is 434 aa.

Mapped IDO75469
Review nameNuclear receptor subfamily 1 group I member 2
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

43
Approved
5
Phase III
18
Phase II
3
Phase I
Assay Mix

Activity Type Distribution

IC50557.0
KI5.0
EC501,358.0
KD1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL463678 9.15 EC50 0.7 Preclinical
CHEMBL5284539 9.0 IC50 1.0 Preclinical
CHEMBL464497 8.82 EC50 1.5 Preclinical
CHEMBL5286515 8.8 IC50 1.6 Preclinical
CHEMBL8739 8.7 EC50 2.0 Preclinical
CHEMBL402063 8.62 IC50 2.4 Preclinical
CHEMBL410683 8.62 IC50 2.4 Preclinical
CHEMBL396952 8.5 EC50 3.162 Preclinical
CHEMBL2103827 8.4 EC50 4.0 Approved
CHEMBL5277255 8.4 IC50 4.0 Preclinical
Distribution

pChEMBL Value Distribution

229
5.0
249
5.5
226
6.0
115
6.5
49
7.0
40
7.5
16
8.0
6
8.5
2
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

DROXIDOPA
CHEMBL2103827
Approved 2014
DABRAFENIB
CHEMBL2028663
Approved 2013
SIROLIMUS
CHEMBL413
Approved 1999
ZAFIRLUKAST
CHEMBL603
Approved 1996
RIMEXOLONE
CHEMBL1200617
Approved 1994
NIMODIPINE
CHEMBL1428
Approved 1988
RIFAMPIN
CHEMBL374478
Approved 1971
Assay Landscape

Assay Landscape

678
Total Assays
488
Tested Compounds
4
Assay Types
Binding — 434 assays, 488 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 216 230 6.1
single protein format 213 251 6.0
assay format 5 7 6.0
ADME — 199 assays, 365 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 112 134 5.3
cell-based format 78 231 5.5
assay format 8 0
tissue-based format 1 0
Functional — 30 assays, 65 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 18 34 7.0
assay format 12 31 5.8
Toxicity — 15 assays, 28 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 11 28 5.2
cell-based format 4 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine